Kalvista Pharmaceuticals Inc宣布，英国药品和医疗产品监管机构(MHRA)已授予EKTERLY®（sebetralstat）营销授权，这款创新口服药物专为遗传性血管性水肿(HAE)发作设计。EKTERLY由此成为英国首个且唯一一款HAE口服按需疗法。 该药物在Kalvista的Salisbury实验室研发，符合MHRA孤儿药认定标准，确保了长达10年的市场独占权。这一里程碑紧随美国FDA近期批准用于12岁及以上青少年和成人之后，进一步加速了Kalvista的全球快速推出战略。 此外，营销授权申请已提交至欧盟、日本及其他关键市场。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.